Compare Amylx Pharmaceuticals Inc (AMLX) vs Mondaycom Ltd (MNDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Mondaycom Ltd — how do they compare? Amylx Pharmaceuticals Inc trades at $23.49 (market cap $2.64B), while Mondaycom Ltd trades at $85.96 (market cap $3.70B). The key difference: Mondaycom Ltd is the larger of the two by market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Mondaycom Ltd nearer its low. Which is the better fit depends on your goals.
| AMLX | MNDY | |
|---|---|---|
Market Cap | $2.64B | $3.70B |
Sector | Health | Technology |
52-Week High | $24.19 | $219.15 |
52-Week Low | $7.82 | $58.81 |
Enterprise Value | $2.39B | $2.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.
The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.
MNDY trades at $84.52, down 4.63% amid mixed signals. The stock shows strong fundamentals with Q2 2026 EPS of $1.48 beating estimates by 33%, revenue growth of 22% year-over-year, and robust gross margins of 88.74%. However, technical indicators are neutral with support at $83 and resistance at $89. Recent news highlights AI product growth but weaker Q3 revenue guidance caused a sell-off.
Outlook remains cautiously optimistic with a $113.38 consensus price target implying 34% upside. Key risks include slowing revenue growth guidance and competitive pressures. The 76% buy rating from analysts supports long-term potential, but near-term volatility may persist due to execution concerns and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →
